Lupin Limited — Board Meeting, 31-03-2025: Outcome of Board Meeting

Lupin Limited's Board has approved the transfer of its API R&D Division to its wholly owned subsidiary, Lupin Manufacturing Solutions Limited, on a slump sale basis, with an expected consideration of ₹17.5 to ₹22.5 crore. Additionally, modifications have been made to the transfer of the Over-the-Counter Consumer Healthcare Business to LUPINLIFE Consumer Healthcare Limited, now including an additional brand. The total expected consideration for this transaction ranges from ₹800 to ₹900 crore. These strategic moves aim to enhance synergies and focus on growth in the respective areas.